"Feb. 4, 2011 -- People unlucky enough to suffer a painful shingles attack had one consolation: the belief it would never happen again.
Now that comforting belief has been shattered. A new study shows that shingles is at least as likely "...
Serious adverse reactions, including anaphylaxis, have occurred with ZOSTAVAX. Adequate treatment provisions, including epinephrine injection (1:1,000), should be available for immediate use should an anaphylactic/anaphylactoid reaction occur.
Transmission of Vaccine Virus
Transmission of vaccine virus may occur between vaccinees and susceptible contacts.
Limitations of Vaccine Effectiveness
Vaccination with ZOSTAVAX does not result in protection of all vaccine recipients.
The duration of protection beyond 4 years after vaccination with ZOSTAVAX is unknown. The need for revaccination has not been defined.
Patient Counseling Information
[See FDA-Approved Patient Labeling.]
- Question the patient about reactions to previous vaccines.
- Provide a copy of the patient information (PPI) located at the end of this insert and discuss any questions or concerns.
- Inform patient of the benefits and risks of ZOSTAVAX, including the potential risk of transmitting the vaccine virus to susceptible individuals, such as immunosuppressed or immunodeficient individuals or pregnant women who have not had chickenpox.
- Instruct patient to report any adverse reactions or any symptoms of concern to their healthcare professional.
Carcinogenesis, Mutagenesis, Impairment of Fertility
ZOSTAVAX has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility.
Use In Specific Populations
Vaccinees and health care providers are encouraged to report any exposure to ZOSTAVAX during pregnancy by calling 1-800-986-8999.
ZOSTAVAX is not indicated in women who are nursing. It is not known whether VZV is secreted in human milk. Therefore, because some viruses are secreted in human milk, caution should be exercised if ZOSTAVAX is administered to a nursing woman.
ZOSTAVAX is not indicated for prevention of primary varicella infection (Chickenpox) and should not be used in children and adolescents.
The median age of subjects enrolled in the largest (N=38,546) clinical study of ZOSTAVAX was 69 years (range 59-99 years). Of the 19,270 subjects who received ZOSTAVAX, 10,378 were 60-69 years of age, 7,629 were 70-79 years of age, and 1,263 were 80 years of age or older.
Last reviewed on RxList: 7/25/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Zostavax Information
Zostavax - User Reviews
Zostavax User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.